Page last updated: 2024-09-02

exp3174 and (6E)-7-[3-(4-fluorophenyl)-1-(propan-2-yl)-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid

exp3174 has been researched along with (6E)-7-[3-(4-fluorophenyl)-1-(propan-2-yl)-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid in 1 studies

Compound Research Comparison

Studies
(exp3174)
Trials
(exp3174)
Recent Studies (post-2010)
(exp3174)
Studies
((6E)-7-[3-(4-fluorophenyl)-1-(propan-2-yl)-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid)
Trials
((6E)-7-[3-(4-fluorophenyl)-1-(propan-2-yl)-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid)
Recent Studies (post-2010) ((6E)-7-[3-(4-fluorophenyl)-1-(propan-2-yl)-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid)
236294332012

Protein Interaction Comparison

ProteinTaxonomyexp3174 (IC50)(6E)-7-[3-(4-fluorophenyl)-1-(propan-2-yl)-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid (IC50)
3-hydroxy-3-methylglutaryl-coenzyme A reductaseHomo sapiens (human)0.0142
Cytochrome P450 2C9 Homo sapiens (human)0.4
Insulin receptor Rattus norvegicus (Norway rat)0.0004
Prostaglandin G/H synthase 2Homo sapiens (human)0.0004
3-hydroxy-3-methylglutaryl-coenzyme A reductase Rattus norvegicus (Norway rat)0.003

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Fukami, T; Hosomi, H; Iwamura, A; Nakajima, M; Yokoi, T1

Other Studies

1 other study(ies) available for exp3174 and (6E)-7-[3-(4-fluorophenyl)-1-(propan-2-yl)-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid

ArticleYear
CYP2C9-mediated metabolic activation of losartan detected by a highly sensitive cell-based screening assay.
    Drug metabolism and disposition: the biological fate of chemicals, 2011, Volume: 39, Issue:5

    Topics: Antihypertensive Agents; Aryl Hydrocarbon Hydroxylases; Benzbromarone; Biotransformation; Cyclooxygenase Inhibitors; Cytochrome P-450 CYP2C9; Diclofenac; HEK293 Cells; Hep G2 Cells; Hepatocytes; Humans; Losartan; NF-E2-Related Factor 2; Semicarbazides; Sensitivity and Specificity; Time Factors; Uricosuric Agents

2011